CBD, eczema and psoriasis: state of the research and the cosmetic framework

The starting point is laboratory work. In 2007, Wilkinson and Williamson published a study in the Journal of Dermatological Science showing that several cannabinoids inhibit the proliferation of human keratinocytes, through a mechanism independent of the CB1 and CB2 receptors. Their conclusion mentions a potential role, phrased in the conditional.

Two limitations must accompany that citation. These are cells in culture, not human beings. And the European document on cosmetic claims is explicit: the presentation of in vitro results must not suggest an in vivo result. This study grounds a hypothesis, not a product promise.

On atopic dermatitis, a randomised double-blind placebo-controlled trial published in 2022 in the Journal of Cosmetic Dermatology compared three arms in 57 participants over fourteen days: a combination of cannabidiol and aspartame, cannabidiol alone, and a placebo. The change in the ISGA score was 1.28 points for the combination, 0.81 for cannabidiol alone and 0.71 for the placebo.

The result that matters is the one commercial communications leave out: the cannabidiol-only arm was not statistically distinguishable from the placebo. Only the combination did better.

On psoriasis, a randomised double-blind placebo-controlled trial published in 2026 in the Journal of Dermatological Treatment followed 28 people with plaque psoriasis receiving 60 mg of oral cannabidiol per day for eight weeks. The authors report that the cannabidiol group showed no significant improvement in the PASI score, with good tolerability. The trial therefore did not meet its primary endpoint.

The other frequently cited studies are of a lower level of evidence: an open-label series of nine people without a control group, and an observational study of sixteen participants whose results rest on self-reported questionnaires. The European document on claims states, moreover, that consumer perception studies are not sufficient to substantiate this type of claim.

A review published in 2025 in the Journal of Cannabis Research sums up the situation: the topical use of cannabinoids remains limited by insufficient clinical experience and the absence of solid evidence on efficacy and safety.

No randomised trial shows that cannabidiol alone improves eczema. No published trial shows a significant reduction in psoriasis severity. The available studies enrolled nine, sixteen, twenty-eight and fifty-seven people, and none lasted beyond twelve weeks, whereas both diseases evolve in flare-ups over decades.

These questions belong to a dermatologist. Our role is to report the state of the publications, not to guide medical care.

This is where the subject becomes precise. Cannabidiol appears in the European CosIng database with declared functions as a skin-conditioning agent, skin protectant, antioxidant and sebum regulator. None of these functions is therapeutic, and that list states exactly the extent of what a cosmetic product may claim.

The legal mechanism fits in one sentence. Article L. 5111-1 of the public health code defines a medicine as any substance or composition presented as possessing curative or preventive properties with regard to human diseases. A cream presented as acting on eczema or psoriasis therefore becomes a medicine by presentation, whatever its actual composition, and then finds itself without a marketing authorisation.

The European regulation on cosmetic claims lays down six common criteria of equal importance: legal compliance, truthfulness, evidential support, honesty, fairness and informed choice. Two of them directly target the shortcuts common in this sector: a claim extrapolating the properties of an ingredient to the finished product must be substantiated, notably by demonstrating the presence of the ingredient at an effective concentration, and the presentation of performance must not go beyond the available evidence.

The European Scientific Committee on Consumer Safety issued on 26 March 2026 a scientific opinion on cannabidiol used in cosmetic products, published on 24 April 2026. In it, cannabidiol is considered safe up to 0.19% in dermal products, with a THC impurity limit of 0.00025%, products likely to lead to exposure by inhalation being excluded from its scope.

Two points of honesty. An opinion of the committee is scientific advice: it becomes binding only if the Commission amends an annex of the cosmetic regulation. And it concerns safety, not efficacy.

The tension deserves to be pointed out: the only skin study with favourable results mentioned above used an ointment dosed at 30% cannabidiol, an order of magnitude far above the concentration assessed as safe by the committee. A product compliant with the safety benchmark is therefore not comparable to the product tested in that open-label series.

Our articles on the cosmetic framework for CBD, on sensitive skin and on oily skin apply the same reading grid. The reported adverse effects are detailed in our dedicated article on side effects.

Can a CBD cream be presented as acting on psoriasis?

No. Psoriasis is a disease, and article L. 5111-1 of the public health code classifies as a medicine any composition presented as having curative or preventive properties with regard to diseases. Such a presentation would tip the product out of cosmetic status, without a marketing authorisation.

What does the only randomised trial testing CBD alone on eczema say?

Published in 2022 in 57 participants over fourteen days, it compared a combination of cannabidiol and aspartame, cannabidiol alone and a placebo. The cannabidiol-only arm was not statistically distinguishable from the placebo on the ISGA score. Only the combination did better than the placebo.

What concentration of CBD can a cosmetic product contain?

In March 2026 the European scientific committee considered cannabidiol safe up to 0.19% in dermal products, with a THC impurity limit of 0.00025%. That opinion concerns safety and amounts neither to recognition of efficacy nor to a regulatory obligation as long as the annexes of the cosmetic regulation remain unamended.